Viatris (HAM:VIA) Short Interest


HAM:VIA Viatris Inc HAM:VIA
58 GF Score
Price €14.26
GF Value €9.77
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Viatris Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

HAM:VIA vs NBIX, UTHR, ELAN: Short Interest Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Viatris's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Viatris Short Interest vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Viatris's Short Interest distribution charts can be found below:

* The bar in red indicates where Viatris's Short Interest falls into.


HAM:VIA
58GF Score
Viatris Inc HAM:VIA
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Viatris (HAM:VIA) Overvalued in 2026?

Based on GuruFocus' analysis, Viatris stock appears to be overvalued. The current stock price of €14.26 is trading 45.9% above its estimated GF Value™ of €9.77. GuruFocus considers Viatris to be Significantly Overvalued.

Key valuation signals for HAM:VIA:

  • Short Interest:
  • GF Value™: €9.77 vs. price of €14.26 (45.9% above fair value)
  • GF Score™: 58/100 with 7 warning signs

No single metric tells the full story. See the HAM:VIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Viatris Business Description

Address 1000 Mylan Boulevard, Canonsburg, PA, USA, 15317
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
58GF Score

Get the complete analysis for HAM:VIA

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€14.26
Price
€9.77
GF Value